Cargando…

Classic Hodgkin Lymphoproliferative Diseases Clonally Unrelated to B-Chronic Lymphocytic Leukemia Successfully Treated with Bendamustine Plus Rituximab

A 62-year-old male was diagnosed with chronic lymphocytic leukemia (CLL) and treated with a fludarabine-containing regimen which maintained the disease in a partial response. Nine years after diagnosis, a rapidly growing systemic lymphadenopathy was observed, and a biopsy specimen revealed the prese...

Descripción completa

Detalles Bibliográficos
Autores principales: Rai, Shinya, Tanaka, Hirokazu, Fujimoto, Ko, Kumode, Takahiro, Inoue, Hiroaki, Taniguchi, Yasuhiro, Morita, Yasuyoshi, Espinoza, J. Luis, Tatsumi, Yoichi, Ashida, Takashi, Matsuoka, Ryota, Kikuti, Yukie Yara, Nakamura, Naoya, Matsumura, Itaru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6162540/
https://www.ncbi.nlm.nih.gov/pubmed/30177612
http://dx.doi.org/10.3390/cancers10090304
_version_ 1783359170688319488
author Rai, Shinya
Tanaka, Hirokazu
Fujimoto, Ko
Kumode, Takahiro
Inoue, Hiroaki
Taniguchi, Yasuhiro
Morita, Yasuyoshi
Espinoza, J. Luis
Tatsumi, Yoichi
Ashida, Takashi
Matsuoka, Ryota
Kikuti, Yukie Yara
Nakamura, Naoya
Matsumura, Itaru
author_facet Rai, Shinya
Tanaka, Hirokazu
Fujimoto, Ko
Kumode, Takahiro
Inoue, Hiroaki
Taniguchi, Yasuhiro
Morita, Yasuyoshi
Espinoza, J. Luis
Tatsumi, Yoichi
Ashida, Takashi
Matsuoka, Ryota
Kikuti, Yukie Yara
Nakamura, Naoya
Matsumura, Itaru
author_sort Rai, Shinya
collection PubMed
description A 62-year-old male was diagnosed with chronic lymphocytic leukemia (CLL) and treated with a fludarabine-containing regimen which maintained the disease in a partial response. Nine years after diagnosis, a rapidly growing systemic lymphadenopathy was observed, and a biopsy specimen revealed the presence of typical Hodgkin/Reed-Sternberg (HRS) cells, surrounded by T-lymphocytes and CLL cells. Sequencing analysis of the germline complementary determining region 3 (CDR3) region of the immunoglobulin heavy chain (IGH) gene showed that the Hodgkin/Reed-Sternberg cells were clonally unrelated to the preexisting CLL cells and the HRS cells were composed of five different clones, leading to the molecular diagnosis of de novo lymphocyte-rich classic Hodgkin lymphoproliferative diseases (LPDs) with small lymphocytic lymphoma (SLL). As the initial treatment was neither effective for classic Hodgkin LPDs nor for SLL, Bendamustine, Rituximab (BR) was started and complete remission was achieved, which has continued for more than one year so far. BR may be a good therapeutic option for both entities without causing hematological toxicity.
format Online
Article
Text
id pubmed-6162540
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-61625402018-10-02 Classic Hodgkin Lymphoproliferative Diseases Clonally Unrelated to B-Chronic Lymphocytic Leukemia Successfully Treated with Bendamustine Plus Rituximab Rai, Shinya Tanaka, Hirokazu Fujimoto, Ko Kumode, Takahiro Inoue, Hiroaki Taniguchi, Yasuhiro Morita, Yasuyoshi Espinoza, J. Luis Tatsumi, Yoichi Ashida, Takashi Matsuoka, Ryota Kikuti, Yukie Yara Nakamura, Naoya Matsumura, Itaru Cancers (Basel) Case Report A 62-year-old male was diagnosed with chronic lymphocytic leukemia (CLL) and treated with a fludarabine-containing regimen which maintained the disease in a partial response. Nine years after diagnosis, a rapidly growing systemic lymphadenopathy was observed, and a biopsy specimen revealed the presence of typical Hodgkin/Reed-Sternberg (HRS) cells, surrounded by T-lymphocytes and CLL cells. Sequencing analysis of the germline complementary determining region 3 (CDR3) region of the immunoglobulin heavy chain (IGH) gene showed that the Hodgkin/Reed-Sternberg cells were clonally unrelated to the preexisting CLL cells and the HRS cells were composed of five different clones, leading to the molecular diagnosis of de novo lymphocyte-rich classic Hodgkin lymphoproliferative diseases (LPDs) with small lymphocytic lymphoma (SLL). As the initial treatment was neither effective for classic Hodgkin LPDs nor for SLL, Bendamustine, Rituximab (BR) was started and complete remission was achieved, which has continued for more than one year so far. BR may be a good therapeutic option for both entities without causing hematological toxicity. MDPI 2018-09-03 /pmc/articles/PMC6162540/ /pubmed/30177612 http://dx.doi.org/10.3390/cancers10090304 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Case Report
Rai, Shinya
Tanaka, Hirokazu
Fujimoto, Ko
Kumode, Takahiro
Inoue, Hiroaki
Taniguchi, Yasuhiro
Morita, Yasuyoshi
Espinoza, J. Luis
Tatsumi, Yoichi
Ashida, Takashi
Matsuoka, Ryota
Kikuti, Yukie Yara
Nakamura, Naoya
Matsumura, Itaru
Classic Hodgkin Lymphoproliferative Diseases Clonally Unrelated to B-Chronic Lymphocytic Leukemia Successfully Treated with Bendamustine Plus Rituximab
title Classic Hodgkin Lymphoproliferative Diseases Clonally Unrelated to B-Chronic Lymphocytic Leukemia Successfully Treated with Bendamustine Plus Rituximab
title_full Classic Hodgkin Lymphoproliferative Diseases Clonally Unrelated to B-Chronic Lymphocytic Leukemia Successfully Treated with Bendamustine Plus Rituximab
title_fullStr Classic Hodgkin Lymphoproliferative Diseases Clonally Unrelated to B-Chronic Lymphocytic Leukemia Successfully Treated with Bendamustine Plus Rituximab
title_full_unstemmed Classic Hodgkin Lymphoproliferative Diseases Clonally Unrelated to B-Chronic Lymphocytic Leukemia Successfully Treated with Bendamustine Plus Rituximab
title_short Classic Hodgkin Lymphoproliferative Diseases Clonally Unrelated to B-Chronic Lymphocytic Leukemia Successfully Treated with Bendamustine Plus Rituximab
title_sort classic hodgkin lymphoproliferative diseases clonally unrelated to b-chronic lymphocytic leukemia successfully treated with bendamustine plus rituximab
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6162540/
https://www.ncbi.nlm.nih.gov/pubmed/30177612
http://dx.doi.org/10.3390/cancers10090304
work_keys_str_mv AT raishinya classichodgkinlymphoproliferativediseasesclonallyunrelatedtobchroniclymphocyticleukemiasuccessfullytreatedwithbendamustineplusrituximab
AT tanakahirokazu classichodgkinlymphoproliferativediseasesclonallyunrelatedtobchroniclymphocyticleukemiasuccessfullytreatedwithbendamustineplusrituximab
AT fujimotoko classichodgkinlymphoproliferativediseasesclonallyunrelatedtobchroniclymphocyticleukemiasuccessfullytreatedwithbendamustineplusrituximab
AT kumodetakahiro classichodgkinlymphoproliferativediseasesclonallyunrelatedtobchroniclymphocyticleukemiasuccessfullytreatedwithbendamustineplusrituximab
AT inouehiroaki classichodgkinlymphoproliferativediseasesclonallyunrelatedtobchroniclymphocyticleukemiasuccessfullytreatedwithbendamustineplusrituximab
AT taniguchiyasuhiro classichodgkinlymphoproliferativediseasesclonallyunrelatedtobchroniclymphocyticleukemiasuccessfullytreatedwithbendamustineplusrituximab
AT moritayasuyoshi classichodgkinlymphoproliferativediseasesclonallyunrelatedtobchroniclymphocyticleukemiasuccessfullytreatedwithbendamustineplusrituximab
AT espinozajluis classichodgkinlymphoproliferativediseasesclonallyunrelatedtobchroniclymphocyticleukemiasuccessfullytreatedwithbendamustineplusrituximab
AT tatsumiyoichi classichodgkinlymphoproliferativediseasesclonallyunrelatedtobchroniclymphocyticleukemiasuccessfullytreatedwithbendamustineplusrituximab
AT ashidatakashi classichodgkinlymphoproliferativediseasesclonallyunrelatedtobchroniclymphocyticleukemiasuccessfullytreatedwithbendamustineplusrituximab
AT matsuokaryota classichodgkinlymphoproliferativediseasesclonallyunrelatedtobchroniclymphocyticleukemiasuccessfullytreatedwithbendamustineplusrituximab
AT kikutiyukieyara classichodgkinlymphoproliferativediseasesclonallyunrelatedtobchroniclymphocyticleukemiasuccessfullytreatedwithbendamustineplusrituximab
AT nakamuranaoya classichodgkinlymphoproliferativediseasesclonallyunrelatedtobchroniclymphocyticleukemiasuccessfullytreatedwithbendamustineplusrituximab
AT matsumuraitaru classichodgkinlymphoproliferativediseasesclonallyunrelatedtobchroniclymphocyticleukemiasuccessfullytreatedwithbendamustineplusrituximab